<p>, /PRNewswire/ --</p>
<p>原因：羅森律師事務所是一家全球投資者權益律師事務所，宣佈代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期間（包括這兩個日期）購買 Jasper Therapeutics, Inc.（納斯達克：JSPR）證券的投資者提起集體訴訟。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 11 月 18 日之前向法院提出申請。</p>
<p>那麼：如果您在集體訴訟期間購買了 Jasper Therapeutics 的證券，您可能有權在不支付任何自付費用或成本的情況下，通過風險代理安排獲得賠償。</p>
<p>接下來該做什麼：要加入 Jasper Therapeutics 的集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=45109 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 11 月 18 日之前向法院提出申請。首席原告是代表其他集體成員指導訴訟的代表方。</p>
<p>為什麼選擇羅森律師事務所：我們鼓勵投資者選擇在領導角色中有成功記錄的合格律師事務所。通常，發佈通知的律師事務所沒有相應的經驗、資源或任何有意義的同行認可。在選擇律師時要明智。羅森律師事務所代表全球投資者，專注於證券集體訴訟和股東衍生訴訟。羅森律師事務所曾在當時獲得針對一家中國公司的最大證券集體訴訟和解。2017 年，羅森律師事務所被 ISS 證券集體訴訟服務評選為證券集體訴訟和解數量第一的律師事務所。自 2013 年以來，該事務所每年都排名前四，併為投資者追回了數億美元。僅在 2019 年，該事務所就為投資者爭取了超過 4.38 億美元的賠償。在 2020 年，創始合夥人 Laurence Rosen 被 law360 評選為原告律師界的巨頭。該事務所的許多律師已獲得 Lawdragon 和 Super Lawyers 的認可。</p>
<p>案件詳情：根據訴訟，被告作出了虛假和/或誤導性的陳述，和/或未能披露以下內容：（1）Jasper 缺乏必要的控制和程序，以確保其依賴的第三方製造商按照 cGMP 法規完全製造產品，並且在臨牀試驗中適用；（2）上述失誤增加了正在進行的研究結果混淆的風險，從而對 Jasper 產品的監管和商業前景產生負面影響，包括 briquilimab；（3）上述失誤增加了採取破壞性成本削減措施的可能性；（4）因此，Jasper 的業務和/或財務前景，以及 briquilimab 的臨牀和/或商業前景被誇大；（5）因此，被告的公開聲明在所有相關時間都是實質性虛假和誤導的。當真實細節進入市場時，訴訟聲稱投資者遭受了損失。</p>
<p>要加入 Jasper Therapeutics 的集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=45109 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。</p>
<p>尚未認證集體。直到集體被認證，您不會被律師代表，除非您聘請一位。您可以選擇自己選擇的律師。您也可以保持缺席集體成員身份，此時不採取任何行動。投資者在任何潛在未來賠償中的分享能力並不依賴於擔任首席原告。</p>
<p>請關注我們的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
<p>律師廣告。之前的結果並不保證類似的結果。</p>
<p>聯繫信息：</p>
<p>Laurence Rosen, Esq.</p>
<p>Phillip Kim, Esq.</p>
<p>羅森律師事務所</p>
<p>275 Madison Avenue, 40th Floor</p>
<p>紐約， NY 10016</p>
<p>電話: (212) 686-1060</p>
<p>免費電話: (866) 767-3653</p>
<p>傳真: (212) 202-3827</p>
<p>[email protected]</p>
<p>www.rosenlegal.com</p>
<p>來源：羅森律師事務所</p>
<p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0"/></p>

JSPR

<p>羅森律師事務所已代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期間購買了 Jasper Therapeutics, Inc.（納斯達克代碼：JSPR）證券的投資者提起集體訴訟。投資者可能有權獲得賠償，無需預付費用。訴訟指控 Jasper 在其製造控制和產品前景方面做出了虛假陳述，導致投資者遭受損失。感興趣的方可以在 2025 年 11 月 18 日之前聯繫該事務所加入集體訴訟</p>

<p>, /PRNewswire/ --</p>
<div class="lb-trans"><p>, /PRNewswire/ --</p>
</div><p>Why: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of securities of Jasper Therapeutics, Inc. (NASDAQ: JSPR) between November 30, 2023 and July 3, 2025, both dates inclusive (the &#34;Class Period&#34;). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025.</p>
<div class="lb-trans"><p>原因：羅森律師事務所是一家全球投資者權益律師事務所，宣佈代表在 2023 年 11 月 30 日至 2025 年 7 月 3 日期間（包括這兩個日期）購買 Jasper Therapeutics, Inc.（納斯達克：JSPR）證券的投資者提起集體訴訟。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 11 月 18 日之前向法院提出申請。</p>
</div><p>So What: If you purchased Jasper Therapeutics securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement.</p>
<div class="lb-trans"><p>那麼：如果您在集體訴訟期間購買了 Jasper Therapeutics 的證券，您可能有權在不支付任何自付費用或成本的情況下，通過風險代理安排獲得賠償。</p>
</div><p>What to do next: To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action. A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than November 18, 2025. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.</p>
<div class="lb-trans"><p>接下來該做什麼：要加入 Jasper Therapeutics 的集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=45109 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。已經提起了集體訴訟。如果您希望擔任首席原告，必須在 2025 年 11 月 18 日之前向法院提出申請。首席原告是代表其他集體成員指導訴訟的代表方。</p>
</div><p>Why Rosen Law: We encourage investors to select qualified counsel with a track record of success in leadership roles. Often, firms issuing notices do not have comparable experience, resources, or any meaningful peer recognition. Be wise in selecting counsel. The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation. Rosen Law Firm achieved the largest ever securities class action settlement against a Chinese Company at the time. Rosen Law Firm was Ranked No. 1 by ISS Securities Class Action Services for number of securities class action settlements in 2017. The firm has been ranked in the top 4 each year since 2013 and has recovered hundreds of millions of dollars for investors. In 2019 alone the firm secured over $438 million for investors. In 2020, founding partner Laurence Rosen was named by law360 as a Titan of Plaintiffs' Bar. Many of the firm's attorneys have been recognized by Lawdragon and Super Lawyers.</p>
<div class="lb-trans"><p>為什麼選擇羅森律師事務所：我們鼓勵投資者選擇在領導角色中有成功記錄的合格律師事務所。通常，發佈通知的律師事務所沒有相應的經驗、資源或任何有意義的同行認可。在選擇律師時要明智。羅森律師事務所代表全球投資者，專注於證券集體訴訟和股東衍生訴訟。羅森律師事務所曾在當時獲得針對一家中國公司的最大證券集體訴訟和解。2017 年，羅森律師事務所被 ISS 證券集體訴訟服務評選為證券集體訴訟和解數量第一的律師事務所。自 2013 年以來，該事務所每年都排名前四，併為投資者追回了數億美元。僅在 2019 年，該事務所就為投資者爭取了超過 4.38 億美元的賠償。在 2020 年，創始合夥人 Laurence Rosen 被 law360 評選為原告律師界的巨頭。該事務所的許多律師已獲得 Lawdragon 和 Super Lawyers 的認可。</p>
</div><p>Details of the case: According to the lawsuit, defendants made false and/or misleading statements and/or failed to disclose that: (1) Jasper lacked the controls and procedures necessary to ensure that the third-party manufacturers on which it relied were manufacturing products in full accordance with cGMP regulations and otherwise suitable for use in clinical trials; (2) the foregoing failure increased the risk that results of ongoing studies would be confounded, thereby negatively impacting the regulatory and commercial prospects of Jasper's products, including briquilimab; (3) the foregoing increased the likelihood of disruptive cost-reduction measures; (4) accordingly, Jasper's business and/or financial prospects, as well as briquilimab's clinical and/or commercial prospects, were overstated; and (5) as a result, defendants' public statements were materially false and misleading at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.</p>
<div class="lb-trans"><p>案件詳情：根據訴訟，被告作出了虛假和/或誤導性的陳述，和/或未能披露以下內容：（1）Jasper 缺乏必要的控制和程序，以確保其依賴的第三方製造商按照 cGMP 法規完全製造產品，並且在臨牀試驗中適用；（2）上述失誤增加了正在進行的研究結果混淆的風險，從而對 Jasper 產品的監管和商業前景產生負面影響，包括 briquilimab；（3）上述失誤增加了採取破壞性成本削減措施的可能性；（4）因此，Jasper 的業務和/或財務前景，以及 briquilimab 的臨牀和/或商業前景被誇大；（5）因此，被告的公開聲明在所有相關時間都是實質性虛假和誤導的。當真實細節進入市場時，訴訟聲稱投資者遭受了損失。</p>
</div><p>To join the Jasper Therapeutics class action, go to https://rosenlegal.com/submit-form/?case_id=45109 or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] for information on the class action.</p>
<div class="lb-trans"><p>要加入 Jasper Therapeutics 的集體訴訟，請訪問 https://rosenlegal.com/submit-form/?case_id=45109 或撥打無障礙電話 866-767-3653 聯繫 Phillip Kim 律師，或發送電子郵件至 [email protected] 獲取有關集體訴訟的信息。</p>
</div><p>No Class Has Been Certified. Until a class is certified, you are not represented by counsel unless you retain one. You may select counsel of your choice. You may also remain an absent class member and do nothing at this point. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.</p>
<div class="lb-trans"><p>尚未認證集體。直到集體被認證，您不會被律師代表，除非您聘請一位。您可以選擇自己選擇的律師。您也可以保持缺席集體成員身份，此時不採取任何行動。投資者在任何潛在未來賠償中的分享能力並不依賴於擔任首席原告。</p>
</div><p>Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm, on Twitter: https://twitter.com/rosen_firm or on Facebook: https://www.facebook.com/rosenlawfirm/.</p>
<div class="lb-trans"><p>請關注我們的 LinkedIn 更新：https://www.linkedin.com/company/the-rosen-law-firm，Twitter：https://twitter.com/rosen_firm 或 Facebook：https://www.facebook.com/rosenlawfirm/。</p>
</div><p>Attorney Advertising. Prior results do not guarantee a similar outcome.</p>
<div class="lb-trans"><p>律師廣告。之前的結果並不保證類似的結果。</p>
</div><p>Contact Information:</p>
<div class="lb-trans"><p>聯繫信息：</p>
</div><p>Laurence Rosen, Esq.</p>
<div class="lb-trans"><p>Laurence Rosen, Esq.</p>
</div><p>Phillip Kim, Esq.</p>
<div class="lb-trans"><p>Phillip Kim, Esq.</p>
</div><p>The Rosen Law Firm, P.A.</p>
<div class="lb-trans"><p>羅森律師事務所</p>
</div><p>275 Madison Avenue, 40th Floor</p>
<div class="lb-trans"><p>275 Madison Avenue, 40th Floor</p>
</div><p>New York, NY 10016</p>
<div class="lb-trans"><p>紐約， NY 10016</p>
</div><p>Tel: (212) 686-1060</p>
<div class="lb-trans"><p>電話: (212) 686-1060</p>
</div><p>Toll Free: (866) 767-3653</p>
<div class="lb-trans"><p>免費電話: (866) 767-3653</p>
</div><p>Fax: (212) 202-3827</p>
<div class="lb-trans"><p>傳真: (212) 202-3827</p>
</div><p>[email protected]</p>
<div class="lb-trans"><p>[email protected]</p>
</div><p>www.rosenlegal.com</p>
<div class="lb-trans"><p>www.rosenlegal.com</p>
</div><p>SOURCE THE ROSEN LAW FIRM, P. A.</p>
<div class="lb-trans"><p>來源：羅森律師事務所</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://rt.prnewswire.com/rt.gif/query-RGF0ZUlkPTIwMjUwOTI3Jk5ld3NJdGVtSWQ9REM4NDcyNCZUcmFuc21pc3Npb25fSWQ9MjAyNTA5MjcxMDM2UFJfTkVXU19VU1BSX19fX19EQzg0NzI0" alt="" original-src="https://rt.prnewswire.com/rt.gif?NewsItemId=DC84724&amp;Transmission_Id=202509271036PR_NEWS_USPR_____DC84724&amp;DateId=20250927"/></p>

JSPR 投資者有機會主導 Jasper Therapeutics, Inc.的證券欺詐訴訟